A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 23, Issue 16, 2017, Pages 4642-4650

  Britten, Carolyn D ^a   Garrett Mayer, Elizabeth ^b   Chin, Steven H ^a,e   Shirai, Keisuke ^a,f   Ogretmen, Besim ^a   Bentz, Tricia A ^b   Brisendine, Alan ^b   Anderton, Kate ^b   Cusack, Susan L ^c   Maines, Lynn W ^c   Zhuang, Yan ^c   Smith, Charles D ^c   Thomas, Melanie B ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c APOGEE BIOTECHNOLOGY CORPORATION   (United States)

^d Gibbs Cancer Center   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) N (4 PYRIDINYLMETHYL)ADAMANTANE 1 CARBOXAMIDE; SPHINGOLIPID; 3-(4-CHLOROPHENYL)-ADAMANTANE-1-CARBOXYLIC ACID (PYRIDIN-4-YLMETHYL)AMIDE; ADAMANTANE; PHOSPHOTRANSFERASE; PYRIDINE DERIVATIVE; SPHINGOSINE KINASE 2, HUMAN;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; AGITATION; AIRWAY OBSTRUCTION; AMNESIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSGEUSIA; FATIGUE; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HEADACHE; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADAMANTANE; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRIDINES; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 85028073704     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2363     Document Type: Article

References (49)

1. Newton J, Lima S, Maceyka M, Spiegel S. Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp Cell Res 2015; 333:195–200.
2. Truman JP, Garcia-Barros M, Obeid LM, Hannun YA. Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta 2014;1841:1174–88.
3. Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog Lipid Res 2016;62: 93–106.
4. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800–3.
5. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 2002;277:25851–4.
6. Marfe G, Mirone G, Shukla A, Di Stefano C. Sphingosine kinases signalling in carcinogenesis. Mini Rev Med Chem 2015;15:300–14.
7. Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem 2014;57:5509–24.
8. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005;106:1808–16.
9. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000;10:1527–30.
10. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005;280:37118–29.
11. Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 2011;9:1509–19.
12. Lynch KR, Thorpe SB, Santos WL. Sphingosine kinase inhibitors: a review of patent literature (2006–2015). Expert Opin Ther Pat 2016;26:1409–16.
13. Santos WL, Lynch KR. Drugging sphingosine kinases. ACS Chem Biol 2015;10:225–33.
14. Igarashi Y, Hakomori S, Toyokuni T, Dean B, Fujita S, Sugimoto M, et al. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry 1989;28: 6796–800.
15. Megidish T, White T, Takio K, Titani K, Igarashi Y, Hakomori S. The signal modulator protein 14–3-3 is a target of sphingosine- or N,N-dimethyl-sphingosine-dependent kinase in 3T3(A31) cells. Biochem Biophys Res Commun 1995;216:739–47.
16. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962–9.
17. Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One 2012;7: e44543.
18. Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J 2012;444:79–88.
19. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, et al. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 2011;54:3524–48.
20. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596–603.
21. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129–39.
22. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010;333:454–64.
23. Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, et al. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011;11:678–89.
24. Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, et al. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther 2014;13:154–64.
25. Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD. Down-regulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression. Mol Cancer Res 2015;13:1591–601.
26. Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, et al. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget 2016;7:20080–92.
27. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, et al. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Mol Cancer Ther 2015;14:2744–52.
28. Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, et al. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 2014;124:1915–25.
29. Wallington-Beddoe CT, Powell JA, Tong D, Pitson SM, Bradstock KF, Bendall LJ. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Res 2014;74:2803–15.
30. Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget 2016;7:60181–92.
31. Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med 2012;237:832–44.
32. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010;151:5124–35.
33. Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011;29: 1132–42.
34. Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xeno-grafts. Cancer Biol Ther 2011;11:524–34.
35. Chumanevich AA, Poudyal D, Cui X, Davis T, Wood PA, Smith CD, et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010;31: 1787–93.
36. Xun C, Chen MB, Qi L, Tie-Ning Z, Peng X, Ning L, et al. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res 2015;34:94.
37. Panneer Selvam S, De Palma RM, Oaks JJ, Oleinik N, Peterson YK, Stahelin RV, et al. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Sci Signal 2015;8:ra58.
38. Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B, et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010;51:3074–87.
39. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A. Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods Mol Biol 2009;579:443–67.
40. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A. Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Adv Exp Med Biol 2010;688: 46–59.
41. Pittet D, Krause KH, Wollheim CB, Bruzzone R, Lew DP. Nonselective inhibition of neutrophil functions by sphinganine. J Biol Chem 1987;262:10072–6.
42. Wilson E, Rice WG, Kinkade JMJr, Merrill AHJr, Arnold RR, Lambeth JD. Protein kinase C inhibition by sphingoid long-chain bases: effects on secretion in human neutrophils. Arch Biochem Biophys 1987;259:204–14.
43. Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, et al. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009;5:184–93.
44. Dickson MA, Carvajal RD, Merrill AHJr, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 2011;17:2484–92.
45. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013;328:9–18.
46. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–15.
47. White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget 2016;7: 23106–27.
48. Muhle C, Reichel M, Gulbins E, Kornhuber J. Sphingolipids in psychiatric disorders and pain syndromes. Handb Exp Pharmacol 2013;216:431–56.
49. Liu R, Zhao R, Zhou X, Liang X, Campbell DJ, Zhang X, et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 2014;60: 908–18.